Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

New combination therapy offers potential lifetime cure for advanced type 1 diabetes

City of Hope researchers developed a combination therapy to treat late-stage type 1 diabetes that appears to offer a potential lifetime cure for the disease without toxic side effects. The laboratory study is published in the May 9 edition of Science Translational Medicine.

11 May 2012

$EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL$

EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL

Cell Therapeutics, Inc. today announced that it has received conditional marketing authorization from the European Commission for Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

11 May 2012

Ixmyelocel-T shows promise against progressive heart failure

An investigational therapy derived from a patient's own bone marrow stem cells improves heart function in some patients with progressive heart failure due to dilated cardiomyopathy (DCM), according to the results of a Phase 2a study presented today as a late-breaking clinical trial at the SCAI 2012 Scientific Sessions.

11 May 2012

$Onconova advances rigosertib into new Phase II study for refractory MDS$

Onconova advances rigosertib into new Phase II study for refractory MDS

Onconova Therapeutics, Inc., announced today the advancement of the oral formulation of rigosertib, an anti-cancer agent with demonstrated activity in solid tumors and hematologic malignancies, into a new Phase II study. The intravenous (IV) formulation of rigosertib is currently in a pivotal Phase III trial for refractory myelodysplastic syndromes (MDS) in the U.S. and EU.

11 May 2012

New non-embryonic stem cell treatment for cancer and leukaemia

A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.

10 May 2012

FDA approves Clinigen’s Foscavir sNDA to treat HIV/AIDS-related CMV infections and herpes

Clinigen Healthcare, the pharmaceutical products division of Clinigen Group, announced today that its supplemental new drug application (sNDA) for Foscavir (foscarnet sodium), a treatment for HIV/AIDS-related cytomegalovirus (CMV) infections and herpes, has been approved by the US Food and Drug Administration.

From Clinigen Group 8 May 2012

T2M cells play a crucial role in treatment-resistant asthma

For most people with asthma, a couple of puffs from an inhaler filled with steroids makes breathing easy. But if their lungs become resistant to the calming effect of that medicine, they live in fear of severe asthma attacks that could send them to the hospital - or worse. Now, new research from the University of Michigan Health System may help explain what's going on in the lungs of these steroid-resistant individuals. The findings could aid the development of new treatment options, and of better ways to identify people at risk of becoming steroid-resistant.

8 May 2012

Positive long-term outcome data for chronic ITP patients treated with rituxamab

A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).

7 May 2012

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Accentia Biopharmaceuticals, Inc. today announced that the Company and leading physicians from Johns Hopkins University co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans.

7 May 2012

Study investigates use of stem cells to treat lower-limb peripheral artery disease

Research led by vascular surgeons at Dartmouth-Hitchcock may offer new hope to sufferers of peripheral artery disease, the cause of nearly 60,000 lower-limb amputations annually, through the use of a patient's own stem cells.

3 May 2012

ASNTR honors UTMSH, MSU scientists with 2012 Sanberg awards

At the 19th Annual Conference of the American Society of Neural Therapy and Repair (ASNTR), held April 26 - 28 in Clearwater Beach, Florida, the ASNTR awarded The 2012 Bernard Sanberg Memorial Award for Brain Repair to Timothy J. Collier, PhD, professor of translational science and molecular medicine at Michigan State University and director of the Udall Center of Excellence in Parkinson's Disease Research at Michigan State University and the University of Cincinnati. ASNTR also presented The Molly and Bernard Sanberg Memorial Award to Sean I. Savitz, MD, associat

2 May 2012

Gilead commences GS-1101 Phase 3 trial in CLL

Gilead Sciences, Inc. today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.

2 May 2012

FANCM gene plays key role in recombination of genetic information during inheritance

Scientists of KIT and the University of Birmingham have identified relevant new functions of a gene that plays a crucial role in Fanconi anemia, a life-threatening disease. The FANCM gene is known to be important for the stability of the genome.

30 Apr 2012

Human iPS cells accrue genetic changes at about the same rate as replicating cells

A team of researchers from Johns Hopkins University and the National Human Genome Research Institute has evaluated the whole genomic sequence of stem cells derived from human bone marrow cells—so-called induced pluripotent stem (iPS) cells—and found that relatively few genetic changes occur during stem cell conversion by an improved method.

30 Apr 2012

Study explores resilin-like materials for vocal fold disorders

A one-inch long grasshopper can leap a distance of about 20 inches. Cicadas can produce sound at about the same frequency as radio waves. Fleas measuring only millimeters can jump an astonishing 100 times their height in microseconds. How do they do it? They make use of a naturally occurring protein called resilin.

27 Apr 2012

FDA ODAC to review Onyx’s NDA for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company's new drug application (NDA) for carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies. ODAC will review carfilzomib at its meeting on June 20, 2012.

27 Apr 2012

Robot assisted laparoscopic radical prostatectomy better than other surgical techniques

Outcomes from use of a robot to assist surgeons in removal of a cancerous prostate are at least as good, if not better, than the other two techniques used for a radical prostatectomy -- open or laparoscopic surgery -- according to a large meta analysis led by researchers at NewYork-Presbyterian/Weill Cornell.

26 Apr 2012

ASH report urges federal agencies to invest in 7 distinct areas of research

The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.

25 Apr 2012

CML and B-ALL arise from the long-term haematopoietic stem cells

Although people generally talk about "cancer", it is clear that the disease occurs in a bewildering variety of forms. Even single groups of cancers, such as those of the white blood cells, may show widely differing properties. How do the various cancers arise and what factors determine their progression? Clues to these two issues, at least for leukaemias, have now been provided by Boris Kovacic and colleagues at the University of Veterinary Medicine, Vienna.

25 Apr 2012

SEBM announces winners of 2012 Best Paper Awards

SEBM is pleased to announce the winners of the Best Paper Awards for articles published in the journal Experimental Biology and Medicine during 2011. SEBM recognizes the best paper annually in each of 3 categories: Clinical/Preclinical and Translation Research, Experimental Biology, and Interdisciplinary Research.

21 Apr 2012

Bone Marrow News and Research

Further Reading

New combination therapy offers potential lifetime cure for advanced type 1 diabetes

EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL

Ixmyelocel-T shows promise against progressive heart failure

Onconova advances rigosertib into new Phase II study for refractory MDS

New non-embryonic stem cell treatment for cancer and leukaemia

FDA approves Clinigen’s Foscavir sNDA to treat HIV/AIDS-related CMV infections and herpes

T2M cells play a crucial role in treatment-resistant asthma

Positive long-term outcome data for chronic ITP patients treated with rituxamab

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Study investigates use of stem cells to treat lower-limb peripheral artery disease

ASNTR honors UTMSH, MSU scientists with 2012 Sanberg awards

Gilead commences GS-1101 Phase 3 trial in CLL

FANCM gene plays key role in recombination of genetic information during inheritance

Human iPS cells accrue genetic changes at about the same rate as replicating cells

Study explores resilin-like materials for vocal fold disorders

FDA ODAC to review Onyx’s NDA for carfilzomib

Robot assisted laparoscopic radical prostatectomy better than other surgical techniques

ASH report urges federal agencies to invest in 7 distinct areas of research

CML and B-ALL arise from the long-term haematopoietic stem cells

SEBM announces winners of 2012 Best Paper Awards

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News